Galapagos plans to cut 100 jobs after striking deal to transfer Jyseleca, 400 staffers to Alfasigma

Galapagos has found a buyer for its once-promising JAK inhibitor Jyseleca (filgotinib), signing a letter of intent to transfer the drug and related operations to Alfasigma of Italy.